Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Rhea-AI Summary

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that CEO Jay R. Luly, Ph.D., will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 3:00 p.m. ET. The event will be accessible via a live webcast on Enanta's website, with a replay available for 90 days. Enanta is focused on developing small molecule drugs targeting viral infections and liver diseases, with key research in areas such as RSV, COVID-19, and HBV, supported by royalties from HCV products developed with AbbVie.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11^th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 3:00 p.m. ET.

A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the event and will be archived for at least 90 days.

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220210005349/en/

Media and Investor Contact

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

What is the date and time of the SVB Leerink Global Healthcare Conference for Enanta Pharmaceuticals?

Enanta Pharmaceuticals will participate in the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 3:00 p.m. ET.

How can I access the live webcast of Enanta Pharmaceuticals' conference participation?

The live webcast of Enanta Pharmaceuticals' participation can be accessed on the 'Events and Presentations' section of the Investors page on their website.

What therapeutic areas does Enanta Pharmaceuticals focus on?

Enanta Pharmaceuticals focuses on developing drugs for viral infections and liver diseases, targeting conditions like RSV, COVID-19, and hepatitis B.

What role do royalties from HCV products play in Enanta Pharmaceuticals' funding?

Enanta's research and development activities are funded by royalties from hepatitis C virus products developed in collaboration with AbbVie.

Who is the CEO of Enanta Pharmaceuticals?

The CEO of Enanta Pharmaceuticals is Jay R. Luly, Ph.D.